Company profile for Revolo Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission. By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach. Existing therapies for autoim...
We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission. By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach. Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
900 Camp Street New Orleans, LA 70130
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/08/05/3127390/0/en/Revolo-Accelerates-Development-of-Orally-Administered-1104-for-Allergic-Diseases.html

GLOBENEWSWIRE
05 Aug 2025

https://www.globenewswire.com/news-release/2025/02/10/3023631/0/en/Revolo-to-Present-at-the-2025-AAAAI-WAO-Joint-Congress.html

GLOBENEWSWIRE
10 Feb 2025

https://www.globenewswire.com/news-release/2024/12/12/2996222/0/en/Revolo-Announces-New-Preclinical-Data-Supporting-Subcutaneous-1104-for-Atopic-Dermatitis-and-Other-Clinical-Programs.html

GLOBENEWSWIRE
12 Dec 2024

https://www.globenewswire.com/news-release/2024/10/21/2966184/0/en/Revolo-Shares-New-Preclinical-Data-Showcasing-the-Potential-of-Sublingual-1104-in-Allergic-Disease.html

GLOBENEWSWIRE
21 Oct 2024

https://www.globenewswire.com/news-release/2024/09/18/2948208/0/en/Revolo-Announces-New-Preclinical-Data-Further-Validating-Atopic-Dermatitis-as-a-Target-Indication-for-1104.html

GLOBENEWSWIRE
18 Sep 2024

https://www.globenewswire.com/news-release/2024/08/07/2925958/0/en/Revolo-Announces-Fireside-Chat-at-Canaccord-Genuity-s-44th-Annual-Growth-Conference.html

GLOBENEWSWIRE
07 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty